Careers

  1. Chemistry
  2. Biology
  3. Pharmacology & Toxicology
  4. IND Application
  5. Operation Support
(Associate) Director of Chemistry
(Associate) Director of Medicinal Chemistry
(Associate)Director of Analytical Chemistry
Assistant Director
Principle Scientist
Senior Manager of Formulation
Team Leader
Senior Scientist
Assistant Scientist
VP Of Medical Chemistry
Director of Biology (structure biology)
Director of Biology (Screening and Sequencing)
Director of Biology (Assay)
VP of Biology
Director of DMPK
Senior Toxicological developer
Director of Pharmacology
Manager of Investigational New Drug Application
VP/Director Business Development
Campus Recruitment
Automation Engineer
VP of Biology

Corporate Vision

  • Innovative Drug Discovery
  • Leading Provider of Leads/Candidates
  • Sustainable Development

With a focus on hit identification and lead generation during the early phase of innovative drug discovery R&D, HitGen aims to be a pioneering enterprise in the pharmaceutical industry with innovative spirit and sustainable development.

Company Overview

HitGen is a biotech company focused on lead generation and optimization of innovative drug discovery research process. HitGen has its headquarters based in Chengdu, China. Its core technology is centered around the synthesis and screening of a rapidly expanding and proprietary DNA-encoded compound libraries of novel small and macrocyclic molecules for lead generation. HitGen has also established key scientific research capabilities of medicinal chemistry, bioscience and computational science with > 200 research staffs. It currently has over 20 preclinical projects on going in oncology, CVD, inflammation/ respiratory, metabolism and ophthalmology. Collaborations with a number of international and domestic pharmaceutical and biotechnology companies have been established.

Core Members of Research Team and Consultant(Partial)

  • Dr. Jin Li — Chairman and Chief Executive Officer

    Dr. Li holds 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.


  • Barry A. Morgan — Chief Scientist Officer

    Barry A. Morgan has broad experience in drug discovery and development. He is Professor and Director of Discovery in the Center for Drug Discovery at Baylor College of Medicine, Houston Texas, and has 40 years of experience in drug discovery and development in the Pharmaceutical and Biotechnology industries in the United Kingdom, France and the USA. He was Vice President, Molecular Discovery, and Site Head at GSK, Boston 2007-2012. He was previously Senior Vice President for Chemistry and Discovery Sciences at Praecis Pharmaceuticals Inc., where he was a primary inventor of DNA Encoded Library Technology. PRAECIS was acquired by GSK in February 2007. inventor of DNA Encoded Library Technology. PRAECIS was acquired by GSK in February 2007. Prior to joining PRAECIS in 2001, he was Director of Chemistry at Biomeasure, Inc., a Boston-based subsidiary of IPSEN Inc. from 1993 to 2001. From 1980 to 1993, he was at Sterling Winthrop Inc., NY, holding positions in Medicinal and Combinatoric Chemistry, and Drug Discovery. While working at Reckitt and Colman in the UK, Barry was seconded to the University of Aberdeen, Scotland where he was responsible for the isolation, structural characterization and synthesis of the enkephalins, the first endogenous opiates. Barry has presented invited seminars at over 50 Academic and Industry Symposia in Europe and the USA, authored over 100 publications, and is an inventor on more than 40 patents in the area of drug discovery. He has contributed to over twenty drug development candidates in a range of therapeutic areas, of which more than ten have been advanced to clinical study. Barry has recruited, managed, and mentored over 100 scientists and 30 interns from the USA, Europe, Asia, Africa, and Australia with B.S. or Ph.D. degrees in chemistry, biology, or computational analysis.
  • Alex Shaginian — Consultant

    Alex Shaginian obtained a Ph. D. in Organic Chemistry at the University of University of Wisconsin–Madison . He was senior scientist for Medicinal Chemistry and Drug Discovery at Ardea Biosciences Inc.( Acquired by AstraZeneca PLC in 2012) from 2007 to 2009 .While working at Ardea Biosciences Inc., Alex developed and patented Ardea’s most potent anti-HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) and the compound was moved into pre-clinical development phase . From 2009 to 2016 , he was Principal Scientist for Molecular Discovery Research at the GlaxoSmithKline PLC., where he pioneered and developed a program that targeted novel chemical space with DNA-encoded library technology and led 3 projects that resulted in identification of new drug candidates for oncology and central-nervous-system targets. He has innovative biotechnology professional with extensive experience in drug discovery and a strong track record of developing and completing complex projects in diverse areas of specialization. Worked in interdisciplinary environments at both large pharmaceutical and small biotechnology companies. He also has deep understanding of corporate finance, accounting, and business strategy.obtained a Ph. D. in Organic Chemistry at the University of University of Wisconsin–Madison . He was senior scientist for Medicinal Chemistry and Drug Discovery at Ardea Biosciences Inc.( Acquired by AstraZeneca PLC in 2012) from 2007 to 2009 .While working at Ardea Biosciences Inc., Alex developed and patented Ardea’s most potent anti-HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) and the compound was moved into pre-clinical development phase . From 2009 to 2016 , he was Principal Scientist for Molecular Discovery Research at the GlaxoSmithKline PLC., where he pioneered and developed a program that targeted novel chemical space with DNA-encoded library technology and led 3 projects that resulted in identification of new drug candidates for oncology and central-nervous-system targets. He has innovative biotechnology professional with extensive experience in drug discovery and a strong track record of developing and completing complex projects in diverse areas of specialization. Worked in interdisciplinary environments at both large pharmaceutical and small biotechnology companies. He also has deep understanding of corporate finance, accounting, and business strategy.

Your Future Workplace

Open, optimistic, positive, spacious and bright work environment.

Take your opportunities and make your career now!


Find Your Balance

  • Christmas Party
    Employees will celebrate Christmas every year since the establishment of HitGen. Different mysterious Santa will show up to give a big surprise. Therefore, be good and Santa may make your dream come true.
  • New Year Party
    New Year party is also a very important annual event for HitGen. All employees will enjoy a joyous gathering and wish a more fruitful and happiness filled new year.
  • Outing
    HitGen will organize 1 or 2 times outing in different places every year, involving all employees as well as their family members to create the harmonious atmosphere among HitGen family.


  • Team Building
    HitGen will organize team-building activity once a year to enhance company cohesion, improve cooperation efficiency between colleagues and deepen their friendship.

  • Stylistic Association
    HitGen has always advocated the spirit of “work harder, play harder”. Currently different teams for badminton, basketball, football, swimming, flower arrangement, baking and drawing have been built, as well as kinds of periodical theme activities, to perfectly balance and enrich employees’ work and life.
  • Public Service Activities
    As a biotechnology company, HitGen has been advocated human-orientated with a high level of corporate social responsibility. HitGen will periodically undertake a series of public service activities to help more people.
  • Staff Meeting
    Staff meeting is one of the most important meetings in HitGen, which enables employees get chance to know the company’s development strategies, project status through quarterly work report made by CEO and department leaders as well as award those teams and individuals with outstanding work performance.

Compensation Package

People are at the core of what we do. We are committed to providing competitive benefits to you and your family, to make HitGen a Great Place to Work.

Compensation and Incentive System

    • Basic salary
    • Performance Related Bonus

    • Project Profit Sharing Bonus
    • Annual Bonus
    • Equity Incentive Plan



Employee Benefits

  • China’s Social Insurance and Housing Fund
  • Breakfast
  • Meal Allowance
  • Birthday Allowance
  • Annual Physical Check
  • Weekly Double Days Off
  • Paid Annual Leave and Sick Leave
  • Holiday Welfare
  • Marriage Leave Allowance
  •  Maternity Leave Allowance
  • Transpotation Allowance

  • Funds for Team Activities


Training & Development

Training System

                     

 



Broad Prospects of Career Development


 Promotion Channels:Management Channel, Technical Channel, Functional Channel

Variety of Job Options Internal Recruitment, Job Rotation